



ASX Release

11 June 2019

ZELDA THERAPEUTICS LIMITED
ACN 103 782 378

Level 26
140 St Georges Terrace,
Perth Western Australia 6000
Tel: +61 8 6558 0886
Fax: +61 8 6316 3337
E: enquiries@zeldatherapeutics.com
W: www.zeldatherapeutics.com

Contacts

Dr Richard Hopkins
Managing Director
+61 405 656 868
rhopkins@zeldatherapeutics.com

Monsoon Communications
Rudi Michelson
+61 3 9620 3333
rudym@monsoon.com

Directors

Dr Richard Hopkins
Mr Harry Karelis
Dr Stewart Washer
Ms Mara Gordon
Mr Jason Peterson

Tickers:

Australia (ASX): ZLD
USA (OTCQB): ZLDAF

Ordinary Shares:
755,341,934

Options:
85,700,000

Director Shareholding Changes and Strategic Investment

- **Zelda Director Ms Mara Gordon has agreed to sell part of her holding to a strategic investor.**
- **Leading boutique investment group Merchant Funds Management acquires 26,931,660 of these shares and now holds a 3.6% stake in the Company**
- **Ms Gordon remains a substantial shareholder and non-executive Director of the Company**
- **Ms Gordon has reconfirmed her commitment not to sell her remaining holding of 44,142,326 shares**
- **Board of Directors owns 27 % of issued capital**
- **Zelda focused on completion of current clinical trials and rapid path to commercialisation and sales in global markets**

Zelda Therapeutics Ltd (ASX: ZLD, OTCQB: ZLDAF, “Zelda” or “the Company”) wishes to update the market that Director Ms Mara Gordon has sold a total of 35,500,000 shares to settle personal commitments and helped facilitate a major investment in Zelda by a strategic investor.

A total of 26,931,660 of these shares have been acquired by leading boutique investment management group Merchant Funds Management (“**Merchant**”). The Company worked with CPS Capital Group to facilitate this investment by Merchant.

Ms Gordon’s shareholding following this sale now stands at 44,142,326 shares and she remains on the Board of the Company.

Following this change in shareholding, the Board of Zelda hold a combined 204,222,646 shares representing 27% of issued capital and remain focused on significantly growing shareholder value.

As per the announcement dated 7 November 2018, the Board confirmed their commitment to not sell any equity securities they own or control (directly or indirectly) unless to help facilitate a major investment in Zelda by a strategic investor.

We welcome the support of Merchant who has a long and successful track record in the Australian medical cannabis sector.

Managing Director of Zelda, Dr Richard Hopkins stated, “*We are delighted to have secured Merchant as a strategic investor in Zelda and welcome their long term support of the Company*”.

Managing Director of Merchant Funds Management, Mr Andrew Chapman stated *"Merchant was an early mover into the Australian medical cannabis sector and enjoys a long association with some of the Founders of Zelda. We believe Zelda has the potential to create significant shareholder value over the next 12 months as clinical trials complete and international commercialisation commences. Developing novel intellectual property combined with a clear path to market is a valuable position to occupy in this rapidly expanding global industry."*

Tim Slate

Company Secretary

About Zelda Therapeutics (www.zeldatherapeutics.com)

Zelda Therapeutics Ltd is an Australian-based bio-pharmaceutical company developing proprietary cannabinoid formulations to treat a variety of medical conditions. The Company is undertaking:

- **Human clinical trials** focused on insomnia, autism and opioid reduction with activities in Australia and the USA.
- **Preclinical research** to examine the effect of cannabinoids in breast, brain and pancreatic cancer and also diabetes-associated cognitive decline.

The company conducts this work in partnership with world-leading researchers and organisations including Complutense University in Madrid, Spain; Curtin University in Perth, Western Australia; the Telethon Kids Institute in Perth; the University of Western Australia, in Perth; St. Vincent's Hospital in Melbourne, Australia; and the Children's Hospital of Philadelphia (CHOP) in the United States

Zelda has also formed strategic partnerships with HAPA Medical BV, to access their EU-GMP grade manufacturing capabilities and their German distribution networks and Ilera Healthcare, a vertically integrated cannabis company with operations in Philadelphia and Louisiana. Together these partnerships provide access to over 110,000 registered medicinal cannabis patients globally for clinically validated Zelda products.